![](https://endpts.com/wp-content/uploads/2022/01/Nenad-Tomasevic-Dren-Bio-tile-scaled.jpg)
Nenad Tomasevic, Dren Bio CEO
Novartis pays $150M upfront, including $25M in equity, for Dren Bio’s bispecifics
Dren Bio inked a research pact with Novartis for select myeloid engagers to treat cancer, marking its second collaboration with a large pharma.
The Swiss …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.